Markets:

Overview

News

Currencies

International

Treasuries

Globus Medical, Inc. Class A Common Stock (NY:GMED)

75.62 -3.39 (-4.29%)

Streaming Delayed Price Updated: 1:38 PM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Globus Medical's Return on Invested Capital Insights ↗

February 21, 2022

Pulled from Benzinga Pro data, Globus Medical (NYSE:GMED) showed a loss in earnings since Q3, totaling $15.11 million. Sales, on the other hand, increased by 8.84% to $250.02...

Via Benzinga

Expert Ratings For Globus Medical ↗

February 18, 2022

Within the last quarter, Globus Medical (NYSE:GMED) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings ↗

February 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...

Via Benzinga

Globus Medical's Q4 Earnings Beat Estimates, But FY22 Outlook Lags ↗

February 18, 2022

Globus Medical Inc's (NYSE: GMED) Q4 sales rea

Via Benzinga

Globus Medical: Q4 Earnings Insights ↗

February 17, 2022

Globus Medical (NYSE:GMED) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 17, 2022 ↗

February 17, 2022

Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.

Via Benzinga

FDA Approves Globus Medical's Consolidated Imaging System ↗

August 17, 2021

The

Via Benzinga

Unusual Options Activity Insight: Globus Medical ↗

August 03, 2021

Globus Medical (NYSE:GMED) shares experienced unusual optio...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios ↗

February 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...

Via Benzinga

Earnings Preview: Globus Medical ↗

February 16, 2022

Globus Medical (NYSE:GMED) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Globus Medical...

Via Benzinga

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2022 ↗

January 04, 2022

Upgrades According to Vertical Research, the prior rating for Livent Corp (NYSE:

Via Benzinga

Why Did BofA Securities Give Globus Medical A Double Upgrade? ↗

December 13, 2021

Enabling tech is likely to continue driving Globus Medical Inc’s (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021 ↗

December 13, 2021

Upgrades According to B of A Securities, the prior rating for Globus Medical Inc (NYSE:

Via Benzinga

Data Rules All in RYAH Group's IoT Solution for Plant-Based Medicine ↗

December 07, 2021

Photo by Franki Chamaki on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

Were Hedge Funds Right About Hyatt Hotels Corporation? ↗

November 10, 2021

The largest stake in Hyatt Hotels Corporation was held by Melvin Capital Management, which reported holding $283.4 million worth of stock at the end of June.

Via Talk Markets

Globus Medical (GMED) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

GMED earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Recap: Globus Medical Q3 Earnings ↗

November 04, 2021

Globus Medical (NYSE:GMED) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:15 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Return on Capital Employed Insights for Globus Medical ↗

August 20, 2021

After pulling data from Benzinga Pro it seems like during Q2, Globus Medical (NYSE:GMED) earned $59.75 million, a 8.98% increase from the preceding quarter. Globus Medical also...

Via Benzinga

Globus Medical (GMED) Q2 2021 Earnings Call Transcript ↗

August 05, 2021

GMED earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Is Globus Medical's Robotic Surgery Business a Winner? ↗

July 29, 2021

It's still early, but things look promising.

Via The Motley Fool

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself ↗

September 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:...

Via Benzinga

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Stocks That Hit 52-Week Highs On Tuesday ↗

July 27, 2021

This morning 85 companies set new 52-week highs. Noteworthy Mentions: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ:GOOG). Intec...

Via Benzinga

The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data ↗

July 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.